Is Ingevity (NGVT) Undervalued Or Is Its Recovery Story Already Priced In?

Simply Wall St.06-27

Ingevity (NGVT) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with fundamentals such as segment mix, recent returns and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646460395?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice1-main-header/1585186700183","is_english":true,"pubTime":"2026-06-27 07:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646460395","market":"nz","top_or_hot":-1,"title":"Is Ingevity (NGVT) Undervalued Or Is Its Recovery Story Already Priced In?","media":"Simply Wall St.","content":"<div>\n<p>Ingevity (NGVT) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with fundamentals such as segment mix, recent returns and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-ngvt/ingevity/news/is-ingevity-ngvt-undervalued-or-is-its-recovery-story-alread\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ingevity (NGVT) Undervalued Or Is Its Recovery Story Already Priced In?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ingevity (NGVT) Undervalued Or Is Its Recovery Story Already Priced In?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-27 07:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/materials/nyse-ngvt/ingevity/news/is-ingevity-ngvt-undervalued-or-is-its-recovery-story-alread><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ingevity (NGVT) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with fundamentals such as segment mix, recent returns and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-ngvt/ingevity/news/is-ingevity-ngvt-undervalued-or-is-its-recovery-story-alread\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NGVT","symbol_name":"Ingevity Corporation When Issued","start_time":0,"source_url":"https://simplywall.st/stocks/us/materials/nyse-ngvt/ingevity/news/is-ingevity-ngvt-undervalued-or-is-its-recovery-story-alread","article_id":"2646460395","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice1-main-header/1585186700183"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-ngvt/ingevity/news/is-ingevity-ngvt-undervalued-or-is-its-recovery-story-alread","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646460395","pubTimestamp":1782515686,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ingevity (NGVT) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with fundamentals such as segment mix, recent returns and profitability trends.\nSee our latest analysis for Ingevity.\nThe latest move takes Ingevity's share price to $77.12, with a 1-month share price return of 11.88% and a year-to-date share price return of 28.34%. The 1-year total shareholder return of 77.86% contrasts with a 5-year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NGVT":"Ingevity Corporation When Issued","BK4109":"特种化学制品"},"translate_title":"Ingevity(NGVT)是否被低估，或者其复苏故事是否已经被定价？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGVT":1.5},"content_text":"Ingevity (NGVT) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with fundamentals such as segment mix, recent returns and profitability trends. See our latest analysis for Ingevity. The latest move takes Ingevity's share price to $77.12, with a 1-month share price return of 11.88% and a year-to-date share price return of 28.34%. The 1-year total shareholder return of 77.86% contrasts with a 5-year total shareholder return that is slightly negative, suggesting strong recent momentum from a weaker longer-term base. If you are looking beyond Ingevity for other opportunities benefiting from similar interest in industrial and materials exposure, this could be a good moment to check out 20 top founder-led companies With Ingevity now at $77.12 and recent returns running ahead of its slightly negative 5-year record, investors face a key question: is the stock still undervalued, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 9.8% Undervalued Based on the most followed valuation narrative, Ingevity's fair value of $85.50 sits above the last close at $77.12, which frames the stock as modestly underpriced against those assumptions.  Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.  Read the complete narrative. Want to see what turns a loss-making Ingevity into a high margin story with a lower future earnings multiple baked in? The narrative leans heavily on profit recovery, shrinking share count and a specific discount rate to support that $85.50 figure. Result: Fair Value of $85.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat Ingevity narrative can be knocked off course if the Advanced Polymer Technologies unit continues to struggle with weaker demand or if tariff related pressures persist and weigh on margins. Find out about the key risks to this Ingevity narrative. Another View: What Multiples Say About Ingevity While the popular Ingevity narrative leans on a fair value of $85.50, the market is currently paying a P/S of 2.3x, compared with 1.1x for the US Chemicals industry and a peer average of 1.3x. The fair ratio is 1.4x, which suggests investors are accepting a richer entry point and less margin for error if the story does not play out as expected. That gap raises a simple question for you as an investor: is the higher P/S a price worth paying for this particular recovery and portfolio reshaping story, or does it tilt the balance of risk and reward too far? See what the numbers say about this price — find out in our valuation breakdown. NYSE:NGVT P/S Ratio as at Jun 2026Next Steps Given the mix of optimism and concern around Ingevity, this is a good moment to move quickly, review the data yourself and decide where you stand by starting with the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Ingevity? If Ingevity's story has you thinking about what else could be worth your attention, use this momentum to widen your watchlist and compare different types of opportunities.  Target quality at a discount by scanning companies that trade below what their fundamentals suggest using the 44 high quality undervalued stocks. Strengthen your portfolio's foundation by reviewing stocks identified in the solid balance sheet and fundamentals stocks screener (48 results). Hunt for lesser-known potential opportunities that others might be overlooking through the screener containing 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646460395","isCrawlerRequest":true}